Jane Street
DNTH icon

Jane Street’s Dianthus Therapeutics DNTH Stock Holding History

Jane Street’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48M Buy
+17,600
New +$1.02M ﹤0.01% 5678
2025
Q4 		– Sell
-25,700
Closed -$1.01M – 11374
2025
Q3 		$1.01M Buy
+25,700
New +$657K ﹤0.01% 6294

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's DNTH Position: Q1 2026 in Review

Jane Street sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 45,833 shares — an estimated $2.65M sold.

Jane Street first reported a position in DNTH in Q4 2023 and held it in 4 quarters. The position peaked at $2.46M in Q1 2024. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Jane Street reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 45,833 Dianthus Therapeutics shares in Q1 2026, an estimated $2.65M.
  • Jane Street first reported a position in Dianthus Therapeutics in Q4 2023 and held it in 4 quarters.
  • Jane Street's Dianthus Therapeutics position peaked at $2.46M in Q1 2024.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.